Axsome Therapeutics (US:AXSM) — Company Overview, News & Financial Data
Axsome Therapeutics develops novel therapies for central nervous system disorders to improve patient outcomes.
About Axsome Therapeutics
Axsome Therapeutics (NASDAQ:AXSM) is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) conditions. Their operations span the entire drug development process, from discovery through clinical trials, with a mission to improve the lives of patients suffering from disorders and diseases affecting the brain and the nervous system. Projects in their pipeline include treatments for major depressive disorder, Alzheimer's disease agitation, and chronic pain, among others. The objective of Axsome is to bring innovative and effective therapeutic solutions to market, addressing unmet medical needs within the realm of CNS disorders, thereby enhancing patient care and outcomes.
Snapshot
Operations
Products and/or services of Axsome Therapeutics
- Sunosi - for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apnea.
- AXS-05 - for Major Depressive Disorder and treatment-resistant depression.
- AXS-07 - for the acute treatment of migraine.
- AXS-12 - for the treatment of narcolepsy.
- AXS-14 - for the management of fibromyalgia.
- AXS-09 - for cognitive disorders including Alzheimer's disease.
Axsome Therapeutics executive team
- Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & President
- Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer
- Mr. Mark L. Jacobson M.A.Chief Operating Officer
- Mr. Hunter Murdock Esq.General Counsel & Secretary
- Mr. Ari MaizelChief Commercial Officer
- Darren OplandDirector of Corporate Communications